Overview

Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

1. Assess the efficacy of varenicline, relative to placebo, on a performance based measure of cognition in patients with mild to moderate Alzheimer's disease 2. Evaluate the effects of varenicline on clinically relevant measures including attention and executive function, behavior, and clinician rated global change. 3. Evaluate the safety and tolerability of varenicline, relative to placebo, in patients with mild to moderate Alzheimer's disease 4. Evaluate the pharmacokinetics of varenicline in patients with mild to moderate Alzheimer's disease.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Varenicline